Abstract
Sepsis is a complex clinical situation responsible for thousands of deaths annually in intensive care units around the globe. Despite all our progress in providing medical care to critically ill patients, mortality of severe forms of sepsis did not decrease as expected. Part of this phenomenon is due to our defective understanding about the host immune response to aggression by a microorganism, including the part played by the pattern-recognition receptors (PRRs) in this process. PRRs are part of the innate immunity responsible for detecting non-self antigens and trigger the initial inflammatory response. The best known PRRs are the tol-like receptors (TLRs). In this article, we review some of our knowledge regarding the role of TLRs in sepsis, both in experimental models and in human patients. The improvement in our knowledge about the mediators and signaling pathways that control this immune response is crucial for the development of better markers of disease and new therapeutic targets, leading us to improve the way we treat septic patients.
Keywords: Pattern recognition receptors, sepsis, toll-like receptors
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Toll-Like Receptors in Sepsis: A Tale Still Being Told
Volume: 10 Issue: 3
Author(s): Heraldo Possolo Souza, Thais Lima-Salgado and Luis Monteiro da Cruz Neto
Affiliation:
Keywords: Pattern recognition receptors, sepsis, toll-like receptors
Abstract: Sepsis is a complex clinical situation responsible for thousands of deaths annually in intensive care units around the globe. Despite all our progress in providing medical care to critically ill patients, mortality of severe forms of sepsis did not decrease as expected. Part of this phenomenon is due to our defective understanding about the host immune response to aggression by a microorganism, including the part played by the pattern-recognition receptors (PRRs) in this process. PRRs are part of the innate immunity responsible for detecting non-self antigens and trigger the initial inflammatory response. The best known PRRs are the tol-like receptors (TLRs). In this article, we review some of our knowledge regarding the role of TLRs in sepsis, both in experimental models and in human patients. The improvement in our knowledge about the mediators and signaling pathways that control this immune response is crucial for the development of better markers of disease and new therapeutic targets, leading us to improve the way we treat septic patients.
Export Options
About this article
Cite this article as:
Possolo Souza Heraldo, Lima-Salgado Thais and Monteiro da Cruz Neto Luis, Toll-Like Receptors in Sepsis: A Tale Still Being Told, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/187153010791936919
DOI https://dx.doi.org/10.2174/187153010791936919 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Hot Topic: Novel Biomarkers in the Prognosis, Progression and Treatment of Cardiovascular Disease: The Role of microRNAs )
Current Topics in Medicinal Chemistry Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Current Medicinal Chemistry Peptide-Based Therapeutic Approaches for Treatment of the Polyglutamine Diseases
Current Medicinal Chemistry Identification of Phenolic Compounds from Nettle as New Candidate Inhibitors of Main Enzymes Responsible on Type-II Diabetes
Current Drug Discovery Technologies The Importance of Growth Hormone (GH) and GH Secretagogues for Bone Mass and Density
Current Pharmaceutical Design Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Nanocarriers for Effective Brain Drug Delivery
Current Topics in Medicinal Chemistry Discovery of JANUVIA <sup>TM</sup> (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type2 Diabetes.
Current Topics in Medicinal Chemistry Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis
Current Medicinal Chemistry Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives
Current Drug Targets Alzheimers Disease (AD) and Mild Cognitive Impairment (MCI) Patients are Characterized by Increased BDNF Serum Levels
Current Alzheimer Research Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using `In silico Pharmacology`
Current Protein & Peptide Science Pharmacology and Clinical Pharmacology of Methylarginines Used as Inhibitors of Nitric Oxide Synthases
Current Pharmaceutical Design Current Status and Perspectives Regarding the Treatment of Osteosarcoma: Chemotherapy
Reviews on Recent Clinical Trials Functional and Molecular Ultrasound Imaging: Concepts and Contrast Agents
Current Medicinal Chemistry Effects of Resveratrol and Other Polyphenols on the Most Common Brain Age-Related Diseases
Current Medicinal Chemistry ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design Conference Report: 12<sup>th</sup> International Congress on Neuroprotective Agents (ICNA), Charlottesville, VA, USA September 28, 2014-Ocobert 01, 2014
CNS & Neurological Disorders - Drug Targets Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design